Mary Slavcev

Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma

Rafaël Fonseca, Saad Z. Usmani, Maneesha Mehra et al. · BMC Cancer · 2020 · 123 citations · Full text

Medicine, Oncology, Cell Therapy +12

Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results

Saad Z. Usmani, María‐Victoria Mateos, Vânia Hungria et al. · Journal of Cancer Research and Clinical Oncology · 2020 · 30 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma

Philippe Moreau, Niels W.C.J. van de Donk, Michel Delforge et al. · Advances in Therapy · 2023 · 28 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Results of a Time and Motion Survey Regarding Subcutaneous versus Intravenous Administration of Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma

Mary Slavcev, Allison Spinelli, Elisabeth Absalon et al. · ClinicoEconomics and Outcomes Research · 2021 · 21 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma

María‐Victoria Mateos, Ajai Chari, Saad Z. Usmani et al. · Clinical Lymphoma Myeloma & Leukemia · 2023 · 15 citations

Medicine, Oncology, Pharmacotherapy +14